Clinical Trials
Phase 3 readouts, new obesity candidates, and the muscle-preservation programs entering the clinic.
The second half of 2026 is unusually dense with readouts. Retatrutide’s TRIUMPH program leads the calendar, followed by next-generation oral GLP-1 candidates and the first phase 2 data for myostatin-pathway combinations aimed at preserving lean mass during incretin therapy.
This tracker page is updated as programs report; each entry links to the underlying registry record and our related coverage.
Interim results from the TRIUMPH program suggest the triple agonist maintains its lead over dual-incretin therapy on weight and liver-fat endpoints.
ResearchAngiogenesis modulation, growth-factor signaling, and the gaps between rodent data and human claims.
ScienceThe August guidance clarifies bulk-substance eligibility and signals enforcement priorities for the next year.
RegulationThe Peptide Institute Weekly
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
